Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Annual Report 2023 Download
Sequana Medical is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer.

alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. The Company has reported positive primary endpoint data from the North American pivotal POSEIDON trial of the alfapump in recurrent or refractory ascites due to liver cirrhosis, enabling the filing of a Pre-Market Approval (PMA) application with the FDA, planned for H2 2023. Having delivered clinical proof-of-concept for DSR as a disease-modifying drug program for the treatment of heart failure, the Company is planning to commence MOJAVE, a US multi-centered randomized controlled Phase 1/2a clinical trial of DSR 2.0, in Q2 2023.

Documents

Article 7:198 juncto articles 7:179, 7:180 and 7:191 of the Belgian companies and Associations Code

Report of the Board of Directors

Report of the Statutory Auditor

Listing prospectus

Listing Prospectus (ENG) (Including E-Disclaimer)

Annual Report 2022

Annual Report (EN)

Reports regarding Kreos Subscription rights

Board Report
Audit Report

Press releases

Contact information

Investor Relations:

Email: IR@sequanamedical.com
Tel: +32 498 053579